Stockscreener 앱 받기
1.435
2.40%
-0.025
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
Price to earnings forward of MAIA Biotechnology, Inc. – BOATS:MAIA - TradingView
MAIAMAIA Biotechnology Inc Dividends - Finviz
ETFs Investing in MAIA Biotechnology, Inc. Stocks - TradingView
MAIA Biotechnology (MAIA) director receives grant of 26,982 stock options - Stock Titan
MAIA Biotechnology (MAIA) director awarded 26,355 stock options at $1.44 - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director receives 32,630 stock options grant - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director granted 27,610 stock options at $1.44 strike - Stock Titan
Director at MAIA Biotechnology (MAIA) receives 32,003 stock options grant - Stock Titan
26,355 stock options granted to MAIA (NASDAQ: MAIA) director Jean-Manasse - Stock Titan
MAIA Q1 2026 Earnings: Narrower Loss Beats Expectations as Clinical Pipeline AdvancesRevenue Report - dars.gov.et
MAIA Biotechnology, Inc. Actuals & Estimates (AMEX:MAIA) - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (BOATS:MAIA) - TradingView
Why Is MAIA Biotechnology (NYSE:MAIA) Tracking Higher on Trial News? - Kalkine Media
MAIA Forecast — Price Target — Prediction for 2027 - TradingView
MAIA finishes THIO-101 enrollment abroad, with 41 lung cancer patients treated - Stock Titan
Why Gold Prices Are CrashingACT NOW! Vincenzo Italiano (pm3QIbzhx7) - Fathom Journal
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer - The Manila Times
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
MAIA Should I Buy - Intellectia AI
Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MAIA Gains on Setting up New Site - Baystreet.ca
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion - GlobeNewswire
Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maia Biotechnology Inc (MAIA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey
Maia Biotechnology Inc (MAIA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MAIA Biotechnology Surges 4.6%, Approaches Key Resistance at $1.43MESA MA - newsline.com
MAIA Biotechnology Holds Steady at $1.30, Consolidating Between Support and ResistanceETF Creation Redemption - newsline.com
MAIA Biotechnology (MAIA) Holds Steady at $1.30 as Consolidation Phase EmergesStock News - newsline.com
MAIA Biotechnology Activates Second US Site for Phase 2 Trial of Lung Cancer Treatment - Moomoo
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - The Manila Times
MAIA Biotechnology Activates and Opens Enrollment at Second - GlobeNewswire
MAIA Q1 2026 Earnings: EPS Beat on Lower Net Loss, Focus on Clinical PipelineConsensus Beat Rate - newsline.com
MAIA Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Consistency Score - newsline.com
FDA Clears US Enrollment for Ateganosine Phase 2 NSCLC Trial Expansion - Targeted Oncology
MAIA Biotechnology Inc. (MAIA) announced that its pivotal Phase III clinical trial for non-small cell lung cancer is showing strong momentum in patient enrollment and dosing. - Bitget
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - The Manila Times
MAIA Biotechnology Reports Patient Enrollment Progress in Phase 3 Trial of Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer - Quiver Quantitative
Lung cancer trial drug saw 17.8-month survival vs 5.8 on chemo in MAIA study - Stock Titan
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion - The Manila Times
FDA clears U.S. trial of MAIA lung cancer drug for third-line patients - Stock Titan
Top MAIA Biotechnology Insiders Make Bold Moves With Fresh Stock Purchases - TipRanks
Maia Biotechnology CSO Sergei Gryaznov buys $2,690 in common stock By Investing.com - Investing.com Canada
MAIA Biotechnology Announces Open Market Purchases by CEO and Director - The Manila Times
MAIA Biotechnology Executives Increase Stock Holdings, Express Confidence in Cancer Immunotherapy Development - Quiver Quantitative
Maia Biotechnology director Stan Smith buys $100,200 in company stock By Investing.com - Investing.com Australia
Maia Biotechnology CEO Vlad Vitoc buys $100,885 in company stock - Investing.com UK
Maia Biotechnology CSO Sergei Gryaznov buys $2,690 in common stock - Investing.com
Maia Biotechnology director Stan Smith buys $100,200 in company stock - Investing.com
Maia Biotechnology CEO Vlad Vitoc buys $100,885 in company stock By Investing.com - Investing.com India
MAIA Biotechnology (MAIA) CEO Vitoc Vlad adds 72,700 shares in open-market buy - Stock Titan
Director Stan Smith adds 75,000 MAIA (NASDAQ: MAIA) shares via trust purchase - Stock Titan
MAIA (MAIA) Chief Scientific Officer purchases 2,000 company shares in market trade - Stock Titan
MAIA (MAIA) CEO awarded 800,000 stock options at $1.39 exercise price - Stock Titan
MAIA Biotechnology (MAIA) grants CSO 400,000 stock options at $1.39 - Stock Titan
MAIA Biotechnology (MAIA) grants 60,000 stock options to head of finance - Stock Titan
1.53%
3.59%
자본화:
|
볼륨(24시간):